Buprenorphine Recall Expanded

Par Health has expanded its recall of Buprenorphine Injection 0.3mg/mL, 1 mL lots – outlined in greater detail via the table below.

First issued in March 2026, this voluntary recall was initiated due to the potential for the presence of white, crystalline product particulates which are comprised of the drug product formulation, principally Buprenorphine free base.

Products in the latest recall were shipped to distributors, including MWI Animal Health, beginning on November 11, 2024.

New Product Recall Information^**

**Review the original announcement for information about products included in the initial recall.

Please take the following actions as soon as possible to ensure that these products are NOT administered to animals:

1. Identify and separate all affected product(s) in your inventory
2. Discontinue use of any affected product(s)
3. Complete the Vendor Response Form (available via PDF) to initiate the return process
4. Submit the form via email to [email protected]

Where to Get Additional Assistance

• Questions or concerns about how your research may be impacted by this recall – including suggestions for alternative medications and assistance with protocol amendments – should be directed to your ULAM Faculty Veterinarian.
  • If you don’t know your faculty veterinarian, please contact the ULAM Business Office ([email protected]), and your question will be routed to the appropriate contact.
• Questions about product returns and/or return processing should be sent to Inmar at 877-545-4693.